Literature DB >> 28168523

Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis.

Felix C Ng1, James Bice2, Anne Rodda2, Matthew Lee-Archer2, Douglas E Crompton2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28168523     DOI： 10.1007/s00415-017-8410-6

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  12 in total

1.  Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion.

Authors:  H C Diener; R Bernstein; K Butcher; B Campbell; G Cloud; A Davalos; S Davis; J M Ferro; M Grond; D Krieger; G Ntaios; A Slowik; E Touzé
Journal:  Int J Stroke       Date:  2016-09-30       Impact factor: 5.266

2.  Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke.

Authors:  Joachim G Schulz; Bernard Kreps
Journal:  J Neurol Sci       Date:  2016-09-09       Impact factor: 3.181

Review 3.  Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.

Authors:  Bart M Demaerschalk; Dawn O Kleindorfer; Opeolu M Adeoye; Andrew M Demchuk; Jennifer E Fugate; James C Grotta; Alexander A Khalessi; Elad I Levy; Yuko Y Palesch; Shyam Prabhakaran; Gustavo Saposnik; Jeffrey L Saver; Eric E Smith
Journal:  Stroke       Date:  2015-12-22       Impact factor: 7.914

4.  Intravenous Thrombolysis With Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant After Antagonization With Idarucizumab.

Authors:  Jörg Berrouschot; Anett Stoll; Theresa Hogh; Christoph Cyrill Eschenfelder
Journal:  Stroke       Date:  2016-06-14       Impact factor: 7.914

5.  Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers.

Authors:  Michael Schmohl; Stephan Glund; Akiko Harada; Susumu Imazu; Marina De Smet; Viktoria Moschetti; Steven Ramael; Ippei Ikushima; Fredrik Grünenfelder; Paul Reilly; Joachim Stangier
Journal:  Thromb Haemost       Date:  2016-12-01       Impact factor: 5.249

6.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

7.  A score to predict early risk of recurrence after ischemic stroke.

Authors:  H Ay; L Gungor; E M Arsava; J Rosand; M Vangel; T Benner; L H Schwamm; K L Furie; W J Koroshetz; A G Sorensen
Journal:  Neurology       Date:  2009-12-16       Impact factor: 9.910

8.  Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report.

Authors:  Waldemar Kafke; Peter Kraft
Journal:  Case Rep Neurol       Date:  2016-06-27

9.  Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report.

Authors:  Johannes Sebastian Mutzenbach; Slaven Pikija; Ferdinand Otto; Ursula Halwachs; Friedrich Weymayr; Johann Sellner
Journal:  Ann Clin Transl Neurol       Date:  2016-09-17       Impact factor: 4.511

10.  Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report.

Authors:  Annemarie Gawehn; Yassine Ayari; Christian Heuschkel; Matthias Kaste; Pawel Kermer
Journal:  J Med Case Rep       Date:  2016-09-29
View more
  7 in total

1.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

2.  Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab.

Authors:  Chee Hoou Loh; Geoffrey Herkes
Journal:  BMJ Case Rep       Date:  2019-05-05

3.  Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.

Authors:  Sergio Agosti; Laura Casalino; Enrico Rocci; Gabriele Zaccone; Eugenia Rota
Journal:  J Med Case Rep       Date:  2017-08-15

Review 4.  Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence.

Authors:  Slaven Pikija; Laszlo K Sztriha; J Sebastian Mutzenbach; Stefan M Golaszewski; Johann Sellner
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

5.  Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.

Authors:  Toshiyuki Ohtani; Ryosuke Sintoku; Tasuku Yajima; Naoyuki Kaneko
Journal:  J Med Case Rep       Date:  2019-12-26

6.  Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature.

Authors:  Senta Frol; Dimitrios Sagris; Janja Pretnar Oblak; Mišo Šabovič; George Ntaios
Journal:  Front Neurol       Date:  2021-06-03       Impact factor: 4.003

7.  Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations.

Authors:  Kazunori Toyoda; Hiroshi Yamagami; Masatoshi Koga
Journal:  J Stroke       Date:  2018-09-30       Impact factor: 6.967
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.